A single gene on the X chromosome that switches "off" when a repeat grows too long. An interactive journey through FMR1, the FMRP protein and its close connection with autism.
The whole journey of this page, summarized in steps.
Before diving into the genetics, it helps to know the condition that the FMR1 gene explains.
Fragile X syndrome is the most common inherited cause of intellectual disability and the most common monogenic cause of autism. It arises when the FMR1 gene, on the X chromosome, switches "off" and stops making the FMRP protein, which is needed for synapses to work well. It is not degenerative: it is a neurodevelopmental disorder.
In 1943, Martin and Bell described an X-linked intellectual disability. In 1969, Lubs observed a "fragile site" —a constriction— on that chromosome. The cause was revealed in 1991: the expansion of the CGG triplet in the FMR1 gene, the starting point for the rest of this page.
The lack of FMRP affects several domains, which combine and vary widely from one person to another:
Mild to moderate intellectual disability (more pronounced in males), language delay, and difficulties with attention and executive function.
Autism spectrum traits (around half of males), social anxiety, gaze avoidance, hyperactivity, sensory hypersensitivity, and hand-flapping or hand-biting.
Long face, large ears, hyperflexible joints and, after puberty in males, macroorchidism (large testes). These tend to become more pronounced with age.
With a single X, they have no healthy copy to compensate: they show the fullest picture of intellectual disability and autistic traits.
Their second, healthy X partly compensates (through random X-inactivation): ranging from almost no symptoms to mild or moderate learning difficulties.
They do not have fragile X, but with age they can develop FXTAS (tremor and ataxia, mainly in older males) or FXPOI (ovarian insufficiency in females).
Unlike Huntington's, the symptoms appear in childhood and then remain relatively stable; there is no progressive deterioration of the brain.
Developmental and language delay, sometimes hypotonia. Physical features are still subtle.
Learning and behavioral difficulties; this is usually when it is diagnosed. Educational support is key.
More pronounced physical features (face, ears, macroorchidism). The condition is stable and does not worsen.
A stable picture. Attention to premutation carriers, who may develop FXTAS or FXPOI.
There is no treatment that repairs the cause, but an early, multidisciplinary approach markedly improves development and independence.
Speech therapy, occupational therapy, special education and behavioral support from an early age: the cornerstone of treatment.
Stimulants for hyperactivity, SSRIs for anxiety and, in specific cases, antipsychotics for severe behaviors. Always as support, not as a cure.
Key for the family: it identifies premutation carriers and provides guidance on the risk of transmission and reproductive options.
Science-based educational content (Martin-Bell syndrome, 1943; FMR1 gene, Verkerk et al. 1991; current clinical practice). It is not a substitute for assessment by a healthcare professional.
The FMR1 gene, on the X chromosome, contains near its start a stretch in which the CGG triplet is repeated. This gene makes the FMRP protein, essential for regulating protein production at synapses.
In most people there are fewer than 45 repeats. When the stretch expands above 200, the gene is chemically "marked" (methylation), is silenced and stops producing FMRP: this is how fragile X syndrome arises.
The FMR1 gene is on the X chromosome, in band Xq27.3 —right at the "fragile site" that gives the syndrome its name—. Because it lies on the X, its inheritance differs from that of other genes.
Unlike Huntington's (which makes a toxic protein), here the problem is the opposite: the repeat grows so much that it silences the gene and the neuron is left without FMRP.
The number of CGG repeats determines whether FMR1 works, produces toxic RNA, or is silenced entirely. Click each range to see what it means.
It shares its mechanism with other repeat expansion diseases. Click a row to see why the same idea produces such different diseases.
| Disease | Gene | Repeat | Threshold | Inheritance |
|---|---|---|---|---|
| Fragile X view → | FMR1 | CGG | ≥ 200 | X-linked |
| Huntington's | HTT | CAG | ≥ 36–40 | Autosomal dominant |
| Myotonic dystrophy type 1 | DMPK | CTG | ≥ 50 | Autosomal dominant |
| Spinocerebellar ataxia type 1 | ATXN1 | CAG | ≥ 39 | Autosomal dominant |
| Friedreich's ataxia | FXN | GAA | ≥ ~70 | Autosomal recessive |
Fragile X is special: the repeat does not create a toxic protein, but instead switches off the gene. Huntington's has its own atlas in this collection.
FMR1 does not act alone: its FMRP protein controls the translation of hundreds of RNAs, many of them autism genes. Click a card to see the details.
FMR1/FMRP at the center and, around it, its partners, its signaling pathway and its targets. Hover over a node to identify it; click to see the details.
From Martin-Bell syndrome to the FMR1 gene and the therapies that aim to reactivate it.
How the loss of FMRP alters the synapse and connects fragile X with autism.
FMRP brakes protein production at dendritic spines. Without it, the spines remain immature and too numerous. Compare the two states.
The FMR1 gene is on the X chromosome. That is why males (with a single X) are usually more affected, whereas females (with two X chromosomes) are carriers or have milder, more variable symptoms.
The premutation (55–200 CGG) can expand to a full mutation when transmitted —only through the maternal line—, so the disease can appear "anew" in the children of a carrier (anticipation). Premutation carriers themselves may develop FXTAS (tremor/ataxia) or FXPOI (ovarian insufficiency).
Adjust the size of the mother's premutation and you'll see the risk that it expands to a full mutation in the son or daughter who inherits that X chromosome. (It only expands through the maternal line.)
Indicative figures (based on Nolin et al.): the risk grows with the size of the premutation; AGG interruptions reduce it. This is not an individual prediction.
The essentials about the genetics of fragile X syndrome:
The key point: fragile X has a very well-defined molecular cause, which makes it a model for understanding autism and intellectual disability. Therapies are being investigated to reactivate FMR1 and correct synaptic signaling.
It is a purely genetic condition. It is not caused by parenting or the environment:
Early intervention greatly improves development, but the cause is always the same: the CGG expansion that silences the FMR1 gene, inherited through the maternal line.
Because of its very well-defined cause, fragile X is one of the leading models for investigating neurodevelopment.
In 2018, FMR1 was reactivated in cultured human neurons by removing the methylation with CRISPR/dCas9, restoring some FMRP. A proof of concept that the "switched-off" gene can be turned back on.
Small AGG interruptions within the CGG repeat stabilize the allele and reduce the risk that the premutation will expand. Today they are measured to fine-tune genetic counseling.
EEG, eye tracking and evoked potentials make it possible to measure brain function objectively, key for trials to detect whether a drug works.
The developing brain is more plastic: intervening in the first years could be decisive for therapies aimed at the cause.
Delivering a functional copy of FMR1 (with AAV vectors) or reactivating the patient's own gene in vivo, the major goals for restoring the FMRP protein.
Antisense oligonucleotides to neutralize the toxic RNA of the premutation, which causes FXTAS in older carriers.
Research is advancing rapidly and some of these results are preliminary: the dates and specific data may change as the trials mature.
The questions that come up most when learning about fragile X syndrome.
Milestones and scientific sources on which this page is based.
A synthesized educational page; it is not a primary clinical source. For medical decisions, consult professionals and the official resources of fragile X organizations.
Six questions to check what you take away. It grades itself: click an answer and you'll instantly see whether you got it right, with the explanation.